Lupin’s Generic Bronchoconstriction Medicine Gains FDA Approval

February 10, 2022

Indian generic drugmaker Lupin got FDA approval for its nebulization-only medicine for long-term maintenance of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

The product — Arformoterol Tartrate Inhalation Solution 15 mcg (base)/2 ml, Unit-dose Vials — is a generic equivalent of Brovana Inhalation Solution, 15 mcg/2 ml, made by Sunovion Pharmaceuticals.

According to IQVIA, Brovana had estimated annual sales of $251million in the U.S. in 2021.

View today's stories